Lucentis


Lucentis received higher average payment on professional claims compared to Outpatient Institutional claims from Medicare

No Image

By: Avinash Kumar  May. 09, 2019

Lucentis is a trade name of Ranibizumab indicated for the treatment of conditions such as Wet Age-related Macular Degeneration (wAMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (mCNV) and Macular Edema following Retinal Vein Occlusion (RVO). Other drugs used for treating Wet Age-related Macular Degeneration (wAMD) are Avastin and Eylea.

Read more